1 – Scarabin PY, Oger E, Plu-Bureau PY on behalf of the Estrogen and THromboEmbolism Risk (ESTHER) Study Group.Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32. (730 citations Web Science)

2 – Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, WahlD, Emmerich J and Scarabin PY on behalf of the EStrogen and THromboEmbolism Risk (ESTHER) Study Group.Hormone therapy and venous thromboembolism among postmenopausal women : impact of the route of estrogen administration and progestogens.  Circulation 2007; 115: 840-5. (634 citations)

3 – Canonico M, Plu-Bureau G, Lowe GD and Scarabin PY. Postmenopausal hormone therapy and risk ofvenous thromboembolism: a systematic review and meta-analysis. British Medical Journal 2008; 336: 1227-31. (556 citations)

4 – Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.  Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women. A Randomised Controlled Trial. Arterioscl Thromb Vasc Biol 1997, 17: 3071-78. (454 citations)

5 – Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort stufy. Arterioscler Thromb Vasc Biol. 2010;30:340-5(266 citations)